Benefit and cost of repeating a severe acute respiratory coronavirus virus 2 (SARS-CoV-2) polymerase chain reaction (PCR) test after the second day of hospitalization in five hospitals during various community prevalences and vaccination rates.


Journal

Infection control and hospital epidemiology
ISSN: 1559-6834
Titre abrégé: Infect Control Hosp Epidemiol
Pays: United States
ID NLM: 8804099

Informations de publication

Date de publication:
01 2023
Historique:
pubmed: 16 6 2022
medline: 20 1 2023
entrez: 15 6 2022
Statut: ppublish

Résumé

At our hospital, universal severe acute respiratory coronavirus virus 2 (SARS-CoV-2) polymerase chain reaction (PCR) testing was performed upon admission and again after 2 inpatient days. As community-wide prevalence, admission, and vaccination rates varied, the number needed to benefit fluctuated between 16 and 769 and the cost per additional detection fluctuated between $800 and $29,400. These 2 metrics were negatively associated with new hospital admissions. No other community indicator was associated with the number needed to benefit and cost per additional detection.

Identifiants

pubmed: 35705231
pii: S0899823X2200157X
doi: 10.1017/ice.2022.157
pmc: PMC9237495
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106-109

Auteurs

Rene Bulnes (R)

Medicine Department, Rochester Regional Health, Rochester, New York.

Mina Said (M)

Medicine Department, Rochester Regional Health, Rochester, New York.

Melissa Bronstein (M)

Quality and Safety Department, Rochester Regional Health, Rochester, New York.

Jennifer Gutowski (J)

Quality and Safety Department, Rochester Regional Health, Rochester, New York.

Karan Alag (K)

Health Informatics, Rochester Regional Health, Rochester, New York.

Jonathan Bress (J)

Medicine Department, Rochester Regional Health, Rochester, New York.

Amber Dellefave (A)

Quality and Safety Department, Rochester Regional Health, Rochester, New York.

Dawn Riedy (D)

Pathology Department, Rochester Regional Health, Rochester, New York.

Jose Alcantara (J)

Health Informatics, Rochester Regional Health, Rochester, New York.

Hiloni Bhavsar (H)

Quality and Safety Department, Rochester Regional Health, Rochester, New York.

Bryan Gargano (B)

Executive Leadership, Rochester Regional Health, Rochester, New York.

Emil Lesho (E)

Infectious Diseases Department, Rochester Regional Health, Rochester, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH